Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

Genetics Investing

Novartis (NYSE:NVS) announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of immuno-oncology therapies. As quoted in the press release: “Our collaborators have combined the fields of immuno-oncology and material science to …

As quoted in the press release:

“Our collaborators have combined the fields of immuno-oncology and material science to develop novel platforms for delivering immunotherapies to combat cancer,” said Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR). “We look forward to collaborating with the Wyss Institute to further develop this technology in conjunction with our growing immunotherapy portfolio.”

Click here to read the full press release.

biomedical biomedical research cancer immuno-oncology immunotherapy novartis oncology Genetics Investing